Influence of cholesterol-lowering on plasma membrane lipids and function

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 18, Issue 2, 1996, Pages 123-136

  Lijnen, P ^a,b   Echevaria Vazquez D ^a   Petrov, V ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cationic transport systems; hypercholesterolemia; hypertension; pravastatin

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; ENDOGENOUS COMPOUND; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROLYTE TRANSPORT; ERYTHROCYTE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; THROMBOCYTE;

ACYL COENZYME A; ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; BLOOD PLATELETS; CELL MEMBRANE; CHOLESTEROL; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ERYTHROCYTES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MEMBRANE LIPIDS; NA(+)-K(+)-EXCHANGING ATPASE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PHOSPHOLIPIDS; PRAVASTATIN; TRIGLYCERIDES;

EID: 0029952453     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. McTavish, D., Sorkin, E.M. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991, 42: 65-80.
2. Tsujita, Y., Kuroda, M., Shimada, Y., Tanzawa, K., Arai, M. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986, 877: 50-60.
3. Mosley, S.T., Kalinowski, S.S., Schafer, B.L., Tanaka, R.D. Tissue selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 1989, 30: 1411-20.
4. Tsujita, Y., Watanabe, Y. Pravastatin sodium: A novel cholesterol-lowering agent that inhibits HMG-CoA reductase. Cardiov Drugs Res 1989, 7. 110-26.
5. Swales, J.D. Functional disturbance of the cell membrane in hypertension. J Hypertension 1990, 8 (Suppl. 7): 203-11.
6. Rutherford, P.A., Thomas, T.H., Wilkinson, R. Erythrocyte sodium-lithium countertransport: Clinically useful, pathophysiologically instructive or just phenomenology? Rev Clin Sci 1992, 82: 341-52.
7. Dominiczak, A.F., Lazar, D.F., Das, A.K., Bohr, D.F. Lipid bilayer in genetic hypertension. Hypertension 1991, 18: 748-57
8. Postnov, Y.V. An approach to the explanation of cell membrane alteration in primary hypertension. Hypertension 1990, 15: 332-7.
9. Cooper, R.A. Abnormalities of cell membrane fluidity in the pathogenesis of disease. New Engi J Med 1977, 297: 371-7.
10. Kimmelberg, H.K. Alterations in phospholipid dependent (Na-K)ATPase activity due to lipid fluidity. Biochim Biophys Acta 1975, 413: 143-6.
11. Grisham, C.M., Barnett, R.E. The effects of long-chain alcohols on membrane lipids and the (Na-K)ATPase. Biochim Biophys Acta 1973, 311: 417-22.
12. Wiley, J.S., Cooper, R.A. Inhibition of cation transport by-cholesterol enrichment of human red cell membranes. Biochim Biophys Acta 1975, 413: 425-31.
13. Jackson, P.A., Morgan, D.B. The relation between membrane cholesterol and phospholipid and sodium efflux in erythrocytes from healthy subjects and patients with chronic cholestasis. Clin Sci 1982, 62: 101-7.
14. Lopes-Virella, M.F., Stone, M., Ellis, S., Colwell, J.A. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977, 23: 882-4.
15. Dobiasova, M. Lecithin cholesterol acyltransferase and the regulation of endogenous cholesterol transport. Adv Lipid Res 1983, 20: 187-94.
16. Chapman, M.J., Goldstein, S., Lagrange, P., Laplaud, P.M. A density gradient ultracentrifugation procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 1981, 22: 339-57.
17. Dagen, M.M., Packard, C.J., Shepherd, J. A comparison of commercial kits for the measurement of lipoprotein (a). Ann Clin Biochem 1991, 28: 359-64.
18. +-cotransport activity in erythrocytes of normal male subjects studied at two occasions. Meth Find Exp Clin Pharmacol 1986, 8: 525-33.
19. McCoy, E.E., Segal, D.J., Bayer, S.M., Strynadka, K.D. Decreased ATPase and increased sodium content of platelets in Down's syndrome. New Engl J Med 1974, 291: 950-3.
20. + fluxes by diuretic drugs in human red cells. Biochem Pharmacol 1984, 33: 2013-20.
21. Canessa, M., Adragna, N., Solomon, H.S., Connolly, T.M., Tosteson, D.C. Increased sodium-lithium countertransport in red cells of patients with essential hypertension. New Engl J Med 1980, 302: 772-6.
22. 3H-ouabain binding by human platelets: Evidence of β-adrenergic stimulation of Na, K-ATPase activity. Metabolism 1989, 38: 773-6.
23. Tsien, R.Y., Pozzan, T., Rink, T.J. Calcium homeostasis in intact lymphocytes: Cytoplasmic-free calcium monitored with a new intracellularly trapped fluorescent indicator. J Cell Biol 1982, 94: 325-34.
24. Duncombe, W.G. The colorimetric micro-determination of long-chain fatty acids. Biochem J 1963, 88: 7-10.
25. Duncombe, W.G. The colorimetric micro-determination of non-esterified fatty acids in plasma. Clin Chim Acta 1964, 9: 122-5.
26. Rose, H.G., Oklander, M. Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res 1965, 6: 428-31.
27. Rudell, L.L., Morris, M.D. Determination of cholesterol using o-phthalaldehyde. J Lipid Res 1973, 14: 364-6.
28. Bartlett, G.R, Phosphorus assay in column chromatography. J Biol Chem 1958, 234: 466-8.
29. Fiske, C.H., Subbarow. Y. The colorimetric determination of phosphorus. J Biol Chem 1925, 66: 375-400.
30. Mathews, J.M.S., Altman, D.G., Campbell, M.J., Royston, P. Analysis of serial measurements in medical research. Brit Med J 1990, 300: 230-5
31. Brown, M.S., Goldstein, J.L. Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980, 21: 505-17.
32. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992, 33: 1569-82.
33. Kovanen, P.T., Bilheimer, D.W., Goldstein, J.L., Jaramillo, J.J., Brown, M.S. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 1987, 78: 1194-8.
34. Bilheimer, D.W., Grundy, S.M., Brown, M.S., Goldstein, J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl acad Sci USA 1983, 80: 4124-8.
35. Brown, M.S., Goldstein, J.L. Lipoprotein receptors in the liver: Control signals for plasma cholesterol traffic. J Clin Invest 1983, 72: 743-7.
36. Goldstein, J.L., Brown, M.S. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem 1977, 46: 897-930.
37. Nakaya, N., Homma, Y., Tamachi, H., Shigematsu, H., Hata, Y., Goto, Y. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic patients. JAMA 1987, 257: 3088-93.
38. Pan, H.Y., de Vault, A.R., Brescia, D., Willard, D.A. Comparative efficacy of once-daily versus twice-daily pravastatin in primary hypercholesterolemia. Clin Ther 1991, 13: 368-72.
39. Vanhanen, H., Kesäniemi, Y.A., Miettinen, T.A. Pravastatin lowers serum cholesterol, cholesterol precursor sterols, fecal steroids and cholesterol absorption in man. Metabolism 1992, 41: 588-95.
40. Vega, G.L., Krauss, R.M., Grundy, S.M. Pravastatin therapy in primary moderate hypercholesterolaemia: Changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990, 227: 81-94.
41. Hoogerbrugge, N., Mol, M J.T.M., Van Dormaal, J.J., Rustenmeijer, C., Muls, E. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med 1990, 228: 261-6.
42. Jones, P.H., Farmer, J.A., Cressman, M.D., McKenny, J.M., Wright, J T. Once-daily pravastatin in patients with primary hypercholesterol: A dose-response study. Clin Cardiol 1991, 14: 146-51.
43. Carmena, R., de Oya, M., Franco, M., Martinez, M.L., Mata, P. Treatment of heterozygous hypercholesterolaemia with pravastatin and/or cholestyramine. 8th Int Symp Atherosclerosis (Oct 9-13. Rome) 1988, 757-60.
44. Wiklund, O., Angelin, B., Fager, G., Eriksson, M., Olofsson, S.O. Treatment of familial hypercholesterolaemia: A controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990, 228: 241-7.
45. Bard, J.M., Parra, H.J., Douste-Blazy, P, Fruchart, J.C. Effect of pravastatin, an HMC-CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 1990, 39: 269-73.
46. Hunninghake, D.B., Mellies, M.J., Goldberg, A.C., Kuo, P.T., Kostis, J.B. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Atherosclerosis 1990, 85: 219-27.
47. Franceschini, G., Sirtori, M., Vaccarino, V., Gianfranceschi, G., Chiesa, G., Sirtori, C.R. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J Lab Clin Med 1989, 114: 250-9.
48. Richter, W.O., Jacob, B.C., Schwandt, P. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins. Int J Tiss React 1991, 13: 107-10.
49. Rubenfire, M., Maciejko, J.J., Blevins, R.D., Orringer, C., Kobylak, L., Rosman, H. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991, 151: 2234-40.
50. Schwartzkopff, W., Bimmermann, A., Schleicher, J. Comparison of the efficacy of pravastatin and cholestyramine in hypercholesterolaemic patients. Arzneim-Forsch/Drug Res 1990, 40: 1322-7.
51. Crepaldi, G., Baggio, G., Arca, M., Avellone, G., Avogaro, P. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I. Arch Intern Med 1991, 151: 146-52.
52. Kortis, J.B., Wilson, A.C., Tannenbaum. A.K., Pan, H.Y., Kuo, P.T. Long-term combination therapy of primary hypercholesterolemia with pravastatin. Circulation 1989, 80 (Suppl. II): 128.
53. Fieseler, H.G., Armstrong, V.W., Wieland, E. et al. Serum Lp(a) concentration are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: Results of a 2-year investigation. Clin Chim Acta 1991, 204: 291-300.
54. Brown, W.V. Lipoproteins: What, when and how often to measure? Heart Disease Stroke 1992, 1: 20-6.
55. Yoshino, G., Kazumi, T, Iwai, M. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects. Atherosclerosis 1988, 71: 95-101.
56. Weisweiler, P. Simvastatin and bezafibrate: Effects on serum lipoproteins and lecithin: Cholesterol acyltransferase activity in familial hypercholesterolaemia. Eur J Clin Pharmacol 1988, 35: 579-83.
57. Desager, J.P., Horsmans, Y., Harvengt, C. Lecithin: Cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. J Clin Pharmacol 1991, 31: 537-42.
58. Miller, N.E., Rajput-Williams, J., Nanjee, M.N., Samuel, L., Albers, J.J. Relationship of high densitiy lipoprotein composition to plasma lecithin: Cholesterol acyltransferase concentration in men. Atherosclerosis 1988, 69: 123-9.
59. Jacob, E.G., Richter, W.O., Schwandt, P. Lovastatin, pravastatin and serum lipoprotein (a). Ann Intern Med 1990, 112: 713-4 .
60. Berg, K., Leren, T.P. Unchanged serum lipoprotein (a) concentrations with lovastatin. Lancet 1989. i: 812
61. Thiery, J., Armstrong, V.W., Schleef, J., Creutzfeldt, C., Creutzfeldt, W., Seidel, D. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG-CoA reductase inhibitor. Klin Wochenschr 1988, 66: 462-3.
62. Jurgens, G., Ashy, A., Zenker, G. Raised serum lipoprotein during treatment with lovastatin. Lancet 1989, i: 911-2.
63. Kostner, G.M., Gavish, D., Leopold, B., Bolzano, K., Weintraub, M.S., Breslow, J.L. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989, 80: 1313-9.
64. M'Bewu, A.D., Durrington, P.N. Lipoprotein (a): Structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990, 85: 1-14.
65. Scanu, A.M., Scandiani, L. Lipoprotein (a): Structure, biology and clinical relevance. Adv Intern Med 1991, 36: 249-70,
66. Bilheimer, D.W., Grundy, S.M., Brown, M.S., Goldstein, J.L. Mevinolin and colestipol stimulate receptor mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983, 80: 4124-8.
67. Weder, A.B., Serr, C., Torretti, B. A., Bassett, D.R., Zweifler, A.J. Effects of lovastatin treatment on red blood cell and platelet cation transport. Hypertension 1991, 17: 203-9.
68. Carr, S.J., Thomas, T.H., Laker, M F., Wilkinson, R. Lipid lowering therapy leads to a reduction in sodium-lithium countertransport activity. Atherosclerosis 1991, 87: 103-8.
69. Brent, G.A., Canessa, M , Dluhy, R.G. Reversible alteration of red cell lithium-sodium countertransport in patients with thyroid disease. J Clin Endocrinol Metab 1989, 68: 322-8.
70. Shohet, S.B Medical progress: Haemolysis and changes in erythrocyte membrane lipids. New Engl J Med 1972, 286: 577-9.
71. Renooij, W., Van Golde, I.M.G. The exchange of phospholipids between rat erythrocyte and plasma, and the translocation of phosphatidylcholine across the red cell membrane, are temperature-dependent processes. FEES Lett 1976, 71: 321-4.
72. Cooper, R.A. Influence of increased membrane cholesterol on membrane fluidity and cell function in human red blood cells. J Supramol Struct 1978, 8: 413-30.
73. Cooper, R.A., Shattil, S.J. Membrane cholesterol. Is enough too much? New Engl J Med 1980, 302: 49-51.
74. Clegg, C., Gledhill, J., Morgan, D.B. Lithium efflux and organic anion exchange in the erythrocytes of patients with chronic cholestasis. IRCS Med Sci 1982, 10: 828-9.
75. Jackson, P.A., Morgan, D.B. The relation between membrane cholesterol and phospholipid and sodium efflux in erythrocytes from healthy subjects and patients with chronic cholestasis. Clin Sci 1982, 62: 101-7.
76. Corrocher, R., Bassi, A., Gandini, A. et al. Transmembrane cation fluxes and fatty acid composition of erythrocytes in psoriatic patients. Clin Chim Acta 1989, 186: 335-44.
77. Kelly, R.A., Canessa, M.L., Steinman, T.J., Mitch, W.E. Hemodialysis and red cell cation transport in uraemia: Role of membrane free fatty acids. Kidney Int 1989, 35: 595-603.
78. Smith, J.B., Wade, M.B., Fineberg, N.S., Weinberger, M.H. Influence of race, sex and blood pressure on erythrocyte sodium transport in humans. Hypertension 1988, 12: 251-8.
79. o countertransport and Li-leak in erythrocytes are differentially affected by membrane enrichment with cholesterol hemisuccinate. Biochim Biophys Acta 1986, 854: 325-8.
80. Claret, M., Garay, R., Giraud, F. The effect of membrane cholesterol on the sodium pump in red blood cells. J Physiol 1978, 274: 247-63.
81. Steinberg, D., Witzum, J.L. Lipoproteins and atherogenesis. Current concepts. JAMA 1990, 264: 3047-52.
82. Castelli, W.P. Cholesterol and lipids in the risk of coronary artery disease - The Framingham Heart Study. Can J Cardiol 1988, 4 (Suppl. A): 5-10A.